Trial Profile
A Double-Blind, Placebo-Controlled, Randomized, Multicenter Phase-II Trial to Assess the Efficacy of Sorafenib Added to Standard Primary Therapy in Patients With Newly Diagnosed AML less than or equal to 60 Years of Age
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 21 Oct 2021
Price :
$35
*
At a glance
- Drugs Sorafenib (Primary) ; Cytarabine; Daunorubicin; Mitoxantrone
- Indications Acute myeloid leukaemia
- Focus Therapeutic Use
- Acronyms SORAML
- 01 Sep 2021 Results assessing to obtain additional data on the clinical course of patients in order to investigate the type and efficacy of second-line treatment in relapsed patients, including rates and modalities of allogeneic stem cell transplantation (allo SCT), cumulative incidence of relapse (CIR) from second complete remission (CR), and survival from first relapse, published in the Leukemia.
- 12 Dec 2017 Long term follow-up results presented at the 59th Annual Meeting and Exposition of the American Society of Hematology
- 05 Nov 2015 Final results published in the Lancet Oncology